Logotipo del repositorio
Logotipo del repositorio
 

Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2eng
dc.contributor.authorPonte-Negretti, Carlos I.
dc.contributor.authorS. Wyss, Fernando
dc.contributor.authorPiskorz, Daniel
dc.contributor.authorD Santos, Raul
dc.contributor.authorVillar, Raul
dc.contributor.authorLorenzatti, Alberto
dc.contributor.authorLópez-Jaramillo, Patricio
dc.contributor.authorToth, Peter
dc.contributor.authorJ. Amaro, A. Juan
dc.contributor.authorRodrigo, Alfonso K.
dc.contributor.authorLanas, Fernando
dc.contributor.authorUrina-Triana, Miguel
dc.contributor.authorLara, Jofre
dc.contributor.authorValdés, T. Osiris
dc.contributor.authorGomez-Mancebo, José R.
dc.contributor.authorBryce, Alfonso
dc.contributor.authorCobos S, Leonardo
dc.contributor.authorPuente-Barragan, Adriana
dc.contributor.authorUllauri-Solórzano, Vladimir E.
dc.contributor.authorMedina-Palomino, Felix A.
dc.contributor.authorLozada, Alfredo F.
dc.contributor.authorDuran, Maritza
dc.contributor.authorBerrospi, Percy
dc.contributor.authorMiranda, David
dc.contributor.authorBadimon, Juan J.
dc.contributor.authorR. González, J. José
dc.contributor.authorLibby, Peter
dc.date.accessioned2021-07-01T16:10:58Z
dc.date.available2021-07-01T16:10:58Z
dc.date.issued2021
dc.description.abstractHypertension, hyperglycemia, dyslipidemia, overweight, obesity, and tobacco (smoking, chewing, and vaping), together with a pro-inflammatory and procoagulant state, are the main risk factors related to atherosclerotic cardiovascular disease. Objective and methods: A group of experts from the Americas, based on their clinical expertise in cardiology, cardiovascular prevention, and cardiometabolic (CM) diseases, joined together to develop these practical recommendations for the optimal evaluation and treatment of residual CM risk factors in Latin America, using a modified Delphi methodology (details in electronic TSI) to generate a comprehensive CM risk reduction guideline, and through personalized medicine and patient-centered decision, considering the cost-benefit ratio The process was well defined to avoid conflicts of interest that could bias the discussion and recommendations. Results: Residual risk reduction should consider therapeutic options adapt- ed to specific patient needs, based on five treatment objectives: triglyceride-rich lipoproteins, inflammation, impaired glucose metabolism, high blood pressure, and prothrombotic status. Comprehensive control of all CM risk factors should be a priority to deal with this important public health problem and prevent premature deaths. The recommendations in this paper address the evidence-based treatment of CM risk and are intended for clinical application in Latin American countries.eng
dc.description.abstractUn grupo de factores de riesgo cardiometabólicos (hipertensión, hiperglucemia, dislipidemia, sobrepeso, obesidad y tabaco (fumado, masticado, vaporizado), junto con un estado proinflamatorio y procoagulante, son los principales factores de riesgo relacionados con la enfermedad cardiovascular aterosclerótica. Objetivo y métodos: Basándose en su experiencia en cardiología, prevención cardiovascular y enfermedades cardiometabólicas, un grupo de expertos de las Améri- cas se unió para desarrollar estas recomendaciones prácticas para la evaluación y tratamiento óptimos de los factores de riesgo cardiometabólicos residuales en América Latina, utilizando una metodología Delphi modificada con el objetivo de generar una guía integral de pautas para la reducción del riesgo cardiometabólico, mediante la medicina personalizada y la decisión centrada en el paciente teniendo en cuenta la relación costo-beneficio. El proceso fue bien definido para evitar conflictos de intereses que podrían sesgar la discusión y las recomendaciones. Resultados: La reducción del riesgo resid- ual debe considerar opciones terapéuticas adaptadas a las necesidades específicas del paciente, basadas en 5 objetivos de tratamiento: lipoproteínas ricas en triglicéridos inflamación, metabolismo de la glucosa, presión arterial alta y estado protrom- bótico. El Control integral de todos los factores de riesgo cardiometabólicos debe ser una prioridad para hacer frente a este importante problema de salud pública y prevenir las muertes prematuras. Las recomendaciones de este documento abordan el tratamiento basado en evidencia del riesgo cardiometabólico y están destinadas a la aplicación clínica en los países de América Latina.spa
dc.format.mimetypepdfspa
dc.identifier.doi10.24875/ACM.21000005
dc.identifier.issn14059940
dc.identifier.urihttps://hdl.handle.net/20.500.12442/7944
dc.identifier.urlhttps://www.archivoscardiologia.com/files/acm_005_21_management.pdf
dc.language.isoengeng
dc.publisherPermanyereng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArchivos de Cardiología de Méxicospa
dc.source(2021)
dc.subjectResidual riskeng
dc.subjectCardiovascular riskeng
dc.subjectCardiometabolic risk factorseng
dc.subjectAtherosclerotic cardiovascular diseaseeng
dc.subjectInflam- mationeng
dc.subjectThrombosiseng
dc.subjectRiesgo residualspa
dc.subjectRiesgo cardiovascularspa
dc.subjectRiesgo cardiometabólicospa
dc.subjectEnfermedad cardiovascular ateroscle- róticaspa
dc.subjectInflamaciónspa
dc.subjectTrombosisspa
dc.titleLatin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)eng
dc.title.translatedConsenso latinoamericano para el manejo del riesgo residual cardiometabólico. Consenso realizado por la Academia Latinoamericana de Lipidología y Riesgo Cardiometabólico (ALALIP), con el aval de la Sociedad Interamericana de Cardiología (SIAC), la Sociedad Interamericana de Aterosclerosis (IAS) y el Colegio Panamericano de Endotelio (PACE)spa
dc.type.driverinfo:eu-repo/semantics/articleeng
dc.type.spaArtículo científicospa
dcterms.referencesGBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of di- sease study 2017. Lancet. 2018;392:1736-88.eng
dcterms.referencesJanuzzi JL Jr., Ahmad T, Binder LG, Hucker WJ, Kumbhani DJ, Maddox TM. et al. 2019 Methodology for creating expert consensus decision pathways: a report of the American college of cardiology. J Am Coll Cardiol. 2019;74:1138-50.eng
dcterms.referencesCrawford M, Wright G. Delphi method. In: Wiley StatsRef: statistics Re- ference Online. United States: Wiley; 2016. p. 1-6.eng
dcterms.referencesFruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual risk reduction initiative (R3i). Residual ma- crovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.eng
dcterms.referencesAverna M, Stroes E, Alterations Beyond LDL Expert Working Group. How to assess and manage cardiovascular risk associated with lipid altera- tions beyond LDL. Atheroscler Suppl. 2017;26:16-24.eng
dcterms.referencesCollins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-61.eng
dcterms.referencesGanda O, Bhatt D, Mason P, Miller M, Boden W. Unmet need for adjunc- tive dyslipidemia therapy in hypertriglyceridemia management. JACC. 2018;72:330-43.eng
dcterms.referencesFerrari R, Catapano AL. Residual cardiovascular risk. Eur Heart J Suppl. 2016;18:C2-12.eng
dcterms.referencesPatel KV, Pandey A, de Lemos JA. Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine. Circulation. 2018;137:2551-3.eng
dcterms.referencesCannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, The- roux P, et al, IMPROVE-IT Investigators. Ezetimibe added to statin the- rapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-97.eng
dcterms.referencesSabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, el al, FOURIER Steering Committee and Investigators. Evo- locumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-22.eng
dcterms.referencesSchwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al, ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097-107.eng
dcterms.referencesBhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al, CM REDUCE-IT Investigators. Cardiovascular risk reduction with icosa- pent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11-22.eng
dcterms.referencesRidker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballan- tyne C, et al, CANTOS Trial Group. Antiinflammatory therapy with cana- kinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31.eng
dcterms.referencesBouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outco- mes after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT). Eur Heart J. 2020;41:4092-9.eng
dcterms.referencesTardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497-505.eng
dcterms.referencesNidorf SM, Fiolet AT, Mosterd A, Eikelboom JW, Schut A, Opstal TS, et al, LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838-47.eng
dcterms.referencesTong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142:1890-900.eng
dcterms.referencesZou CY, Liu XK, Sang YQ, Wang B, Liang J. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in Type 2 diabetes: a me- ta-analysis. Medicine (Baltimore). 2019;98:e18245.eng
dcterms.referencesSinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;150:8-16.eng
dcterms.referencesBittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual anti- platelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/ American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2016;68:1116-39.eng
dcterms.referencesBonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al, PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800.eng
dcterms.referencesEikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestako- vska O, et al, COMPASS Investigators. Rivaroxaban with or without as- pirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319-30.eng
dcterms.referencesYusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income coun- tries (PURE): a prospective cohort study. Lancet. 2020;395:795-808.eng
dcterms.referencesRana JS, Liu JY, Moffet HH, Boklage SH, Khan I, Karter AJ. Risk of in- cident atherosclerotic cardiovascular disease events by achieved athero- genic lipid levels among 62,428 statin-treated individuals with diabetes mellitus. Am J Cardiol. 2018;122:762-7.eng
dcterms.referencesCholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.eng
dcterms.referencesSabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in pa- tients starting with very low levels: a meta-analysis. JAMA Cardiol. 2018;3:823-8.eng
dcterms.referencesFerence BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular di- sease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society con- sensus panel. Eur Heart J. 2017;38:2459-72.eng
dcterms.referencesMundi S, Massaro M, Scoditti E, Carluccio MA, van Hinsbergh VW, Iruela-Arispe ML, et al. Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review. Cardiovasc Res. 2018;114:35-52.eng
dcterms.referencesSilverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduc- tion among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289-97.eng
dcterms.referencesNordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic car- diovascular disease: new insights from epidemiology, genetics, and bio- logy. Circ Res. 2016;118:547-63.eng
dcterms.referencesMasana L, Girona J, Ibarretxe D, Rodríguez-Calvo R, Rosales R, Vallvé JC, et al. Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis. J Clin Lipi- dol. 2018;12:292-9.e3.eng
dcterms.referencesGiugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, EBBIN- GHAUS Investigators. Cognitive function in a randomized trial of evolo- cumab. N Engl J Med. 2017;377:633-43.eng
dcterms.referencesGiugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al, FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhi- bitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962-71.eng
dcterms.referencesDitlev C, Johannesen L, Bødtker Mortensen M, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77:1439-50.eng
dcterms.referencesBallantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY) II. Am Heart J. 2006;151:975.e1-9.eng
dcterms.referencesPerrone V, Sangiorgi D, Buda S, Degli Esposti L. Residual cardiovascu- lar risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study. Clinicoecon Outcomes Res. 2016;8:649-55.eng
dcterms.referencesJohansen CT, Hegele RA. Using mendelian randomization to determine causative factors in cardiovascular disease. J Intern Med. 2013;273:44-7.eng
dcterms.referencesPonte-Negretti CI, Isea-Perez JE, Lorenzatti AJ, Lopez-Jaramillo P, Wyss-Q FS, Pintó X, et al. Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment: expert’s position paper made by the Latin American academy for the study of lipids (ALALIP) endorsed by the inter-American society of cardiology (IASC), the South American society of cardiology (SSC), the Pan-American college of endothelium (PACE), and the international atherosclerosis society (IAS). Int J Cardiol. 2017;243:516-22.eng
dcterms.referencesVillines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, et al. The ARBITER 6-HALTS trial (Arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL Treatment Stra- tegies in Atherosclerosis): final results and the impact of medication adhe- rence, dose, and treatment duration. J Am Coll Cardiol. 2010;55:2721-6.eng
dcterms.referencesAIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chait- man BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67.eng
dcterms.referencesACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr., Grimm RH Jr., Cutler JA, et al. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.eng
dcterms.referencesScott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, et al. Fe- nofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: the fenofibrate intervention and event lowe- ring in diabetes (FIELD) study. Diabetes Care. 2009;32:493-8.eng
dcterms.referencesORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309-18.eng
dcterms.referencesThe ASCEND Study Collaborative Group. Effects of n-3 fatty acid supple- ments in diabetes mellitus. N Engl J Med 2018;379:1540-50.eng
dcterms.referencesAung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al, Omega-3 Treatment Trialists’ Collaboration. Associations of Ome- ga-3 fatty acid supplement use with cardiovascular disease risks: me- ta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol. 2018;3:225-34.eng
dcterms.referencesPonte-N C, Machado HL. Lipidología y prevención cardiovascular La era de las combinaciones llegaron para quedarse. JACC Spanish Ed 2020;1:120-3.eng
dcterms.referencesFord I, Murray H, McCowan C, Packard CJ. Long-term safety and effica- cy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of Scotland coronary prevention study. Circu- lation. 2016;133:1073-80.eng
dcterms.referencesThanassoulis G, Sniderman AD, Pencina MJ. A long-term benefit approach vs standard risk-based approaches for statin eligibility in pri- mary prevention. JAMA Cardiol. 2018;3:1090-5.eng
dcterms.referencesWilleit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin out- come trials. Lancet. 2018;392:1311-20.eng
dcterms.referencesVerbeek R, Hoogeveen RM, Langsted A, Stiekema LC, Verweij SL, Hovingh GK, et al. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39:2589-96.eng
dcterms.referencesBertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9:25.eng
dcterms.referencesLow Wang CC, Everett BM, Burman KD, Wilson PW. Cardiovascular safety trials for all new diabetes mellitus drugs? Circulation. 2019;139:1741-3.eng
dcterms.referencesRay KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2017;24:44-51.eng
dcterms.referencesVerma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovas- cular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108-17.eng
dcterms.referencesZinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al, The EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373: 2117-28.eng
dcterms.referencesNeal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al, CANVAS Program Collaborative Group. Canagliflozin and cardio- vascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377: 644-57.eng
dcterms.referencesWiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al, MS DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular out- comes in Type 2 diabetes. N Engl J Med. 2019;380:347-57.eng
dcterms.referencesKluger AY, Tecson KM, Barbin CM, Lee AY, Lerma EV, Rosol ZP, et al. Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EM- PA-REG OUTCOME trials: a systematic review. Rev Cardiovasc Med. 2018;19:41-9.eng
dcterms.referencesPacker M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al, EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outco- mes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24.eng
dcterms.referencesMcMurray JJ, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Lang- kilde AM, et al, DAPA-HF Committees and Investigators. A trial to eva- luate the effect of the sodium-glucose co-transporter 2 inhibitor dapagli- flozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21: 665-75.eng
dcterms.referencesHeerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al, DAPA-CKD Trial Committees and Investigators. Dapagli- flozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46.eng
dcterms.referencesMarso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al, LEADER Steering Committee, LEADER Trial Investiga- tors. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375:311-22.eng
dcterms.referencesMarso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outco- mes in patients with Type 2 diabetes. N Engl J Med. 2016;375:1834-44.eng
dcterms.referencesGerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al, REWIND Investigators. Dulaglutide and cardiovascular outcomes in Type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-30.eng
dcterms.referencesWyss F, Coca A, Lopez-Jaramillo P, Ponte-Negretti C. The Task Force for the Management of Arterial Hypertension of the Interamerican Socie- ty of Cardiology (IASC), Reviewers from the European Society of Hyper- tension (ESH), Latin-American Society of Hypertension (LASH), and the Spanish Society of Cardiology (SSC). Position statement of the Intera- merican society of cardiology (IASC) on the current guidelines for the prevention, diagnosis and treatment of arterial hypertension 2017-2020. Int J Cardiol Hypertens. 2020;6:100041.eng
dcterms.referencesRidker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Za- harris E, CIRT Investigators. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752-76.eng
dcterms.referencesCapell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, et al. Rationale and design for the vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018;199:83-91.eng
dcterms.referencesAnand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al, COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomi- sed, double-blind, placebo-controlled trial. Lancet. 2018;391:219-29.eng
dcterms.referencesMega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al, ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.eng
dcterms.referencesNocon M, Hiemann T, Müller-Riemenschneider F, Thalau F, Roll S, Wi- llich SN. Association of physical activity with all-cause and cardiovascu- lar mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil. 2008;15:239-46.eng
dcterms.referencesAmerican Heart Association. Council on Lifestyle and Cardiometabolic Health. Available from: https://www.professional.heart.org/professional/ MembershipCouncils/ScientificCouncils/UCM_322856_Council-on-Lifes- tyle-and-Cardiometabolic-Health.jsp. [Last accessed on 2018 Sep 19eng
dcterms.referencesMente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coro- nary heart disease. Arch Intern Med. 2009;169:659-69.eng
dcterms.referencesBarua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri MA, Morris PB, et al. 2018 ACC expert consensus decision pathway on to- bacco cessation treatment: a report of the American college of cardiolo- gy task force on clinical expert consensus documents. J Am Coll Cardiol. 2018;72:3332-65.eng
dcterms.referencesSosa-Liprandi Á, Sosa Liprandi MI, Alexánderson E, Avezum Á, Lanas F, López-Jaramillo JP, et al. Clinical impact of the polypill for cardiovascular prevention in Latin America: a consensus statement of the inter-American society of cardiology. Glob Heart. 2019;14:3-16.e1.eng
oaire.versioninfo:eu-repo/semantics/publishedVersioneng

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Latin American Concensus on management of residual cardiometabolic risk.pdf
Tamaño:
1.59 MB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca